The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Tucatinib (TUC) combined with trastuzumab and pertuzumab (HP) as first-line (1L) maintenance therapy for HER2+ metastatic breast cancer (MBC): an in-depth safety analysis of HER2CLIMB-05
Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, Pimentel L, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Sohn J, Silva EC, Mueller V, Kaur M, Viala H, Yang S, Hamilton E
Presentation
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups
Hamilton E, Curigliano G, Martin M, Lerebours F,Tsurutani J, Savard MF, Hu X, Pimentel L, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Mueller V, Viala H, Tan S,Feng W, Shen Q, Dieras V
Presentation
Addition of tucatinib to trastuzumab emtansine (T-DM1) in patients with previously treated HER2+ locally advanced/metastatic breast cancer (LA/MBC): updated efficacy analysis from the HER2CLIMB-02 trial
Curigliano G, Borges V, O’Shaughnessy J, Okines A, Tolaney SM, Saura C, Wolff AC, Loi S, Masuda N, Vahdat L, Xu B, Chiu D, Xie D, Abbasi N, Olu K, Hurvitz SA
Presentation
HER2CLIMB-05: A randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer
Hamilton E, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard M, Jerzak K, Hu X, Martins de Aquino Pimentel L, O'Sullivan C, Tokunaga E, Okines A, Huang C, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Santarpia L, Dieras V
Presentation
Tucatinib and Trastuzumab for Patients With Previously Treated, HER2-Altered Solid Tumors (SGNTUC-019): A Phase 2 Basket Study
Nakamura Y, Bekaii-Saab T, Hamilton E, Hayashi H, Mizuno N, Monk BJ, Nguyen D, Okines A, O’Malley DM, Pohlmann PR, Pothuri B, Reck M, Sudo K, Sunakawa Y, Takahashi S, Yu EY, Drees A, Tan S, Stinchcombe TE